Vertaling van "Rate " (Frans → Nederlands) :

TERMINOLOGIE

Rate
milt

rate
lien

Rupture de la rate, non traumatique Torsion de la rate
miltruptuur, niet-traumatisch | torsie van milt

Appareil digestif SAI Intestin SAI Rate
darm NNO | milt | tractus digestivus NNO

Maladies de la rate
ziekten van milt

Paludisme à Plasmodium vivax, avec rupture de la rate
malaria door Plasmodium vivax met miltruptuur

structure de la rate
milt

intervention chirurgicale de la rate
miltoperatie

rupture traumatique de la rate
traumatische ruptuur van milt

Asplénie post-chirurgicale Atrophie de la rate
asplenie, na operatie | atrofie van milt

IN-CONTEXT TRANSLATIONS

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Tableau 1. Survival, pregnancy and delivery rates after single embryo transfer of human blastocysts vitrified with either the Cryotop or the CryoTip method Cryotop TM (ouvert) Cryotip TM (fermé) Survived/vitrified rate (%) 221/227 (97) 82/88 (93) Pregnancy/transfer rate (%) 131/221 (59) 42/82 (51) Delivery/transfer rate (%) 113/221 (51) 39/82 (48)
Tabel 1. Survival, pregnancy and delivery rates after single embryo transfer of human blastocysts vitrified with either the Cryotop or the CryoTip method. Cryotop (open) Cryotip (gesloten) Survived/vitrified rate (%) 221/227 (97) 82/88 (93) Pregnancy/transfer rate (%) 131/221 (59) 42/82 (51) Delivery/transfer rate (%) 113/221 (51) 39/82 (48) No significant differences between corresponding values were found.

Tableau 2: Comparison of survival, implantation and pregnancy rates according to loading device Loading Device Sample Size Survival Rate Implantation Rate Pregnancy Rate
Tabel 2: Comparison of survival, implantation and pregnancy rates according to loading device. Loading Device Sample Size Survival Rate Implantation Rate Pregnancy Rate

AFCN Agence Fédérale de Contrôle Nucléaire CT Computer Tomography CRT Radiotherapie Conformelle EBRT External Beam Radiotherapy HDR High dose Rate IGRT Image-Guided RadioTherapy IMRT Intensity Modulated Radiation Therapy INAMI Institut National d’Assurance Maladie-Invalidité IPSS International Prostate Symptom Score LDR Low Dose Rate MRI Magnetic Resonance Imaging PDR Pulsed Dose Rate PSA Prostaat specifiek antigeen QO Quartier Opératoire TURP resection transurethrale de la prostate
CT Computer Tomography CRT Conformele RadioTherapie EBRT External Beam RadioTherapy FANC Federaal Agentschap Nucleaire Controle HDR High Dose Rate IGRT Image-Guided RadioTherapy IMRT IntensiteitsgeModuleerde RadioTherapie IPSS International Prostate Symptom Score LDR Low Dose Rate MRI Magnetic Resonance Imaging OK OperatieKwartier PDR Pulsed Dose Rate PSA Prostaat Specifiek Antigen RIZIV Rijksdienst voor Ziekte en InvaliditeitsVerzekering TURP TransUrethrale Resectie van de Prostaat

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

It is computed as the difference between the overall rate in the population and the rate in the more advantaged group, divided by the overall rate in the population.
It is computed as the difference between the overall rate in the population and the rate in the more advantaged group, dividedd by the overall rate in the population. In this chapter, we highlighted the indicators for which we observed a relative risk (RR) as large as 1.2 (or 0.83 when the gradient was reverse).

Middle trimester, perinatal death rate: In white women (n = 10,074): – without proteinuria and < 90 mmHg = 15.2 – without proteinuria and º 90 mmHg = 25.8 – with proteinuria and < 90 mmHg = 38.5 – with proteinuria and º 90 mmHg = 17.0 In black women (n = 2880): – without proteinuria
perinatal death rate: In white women (n = 10,074): – without proteinuria and < 90 mmHg = 15.2 – without proteinuria and º 90 mmHg = 25.8 – with proteinuria and < 90 mmHg = 38.5 – with proteinuria and º 90 mmHg = 17.0 In black women (n = 2880): – without proteinuria and < 90 mmHg = 20.3 – without proteinuria and º 90 mmHg = 34.6 – with proteinuria and 90 mmHg = 56.6 – with proteinuria and º 90 mmHg = 142.9

Middle trimester, stillbirth rate: In white women (n = 10,074): – without proteinuria and < 90mmHg = 8.4 – without proteinuria and º 90 mmHg = 14.8
hypertension alone: 24.8% vs. 13.8%, p < 0.001 Page and 4 [516b] 12,954 singleton Fetal mortality In third trimester: CH Christianso pregnancies in and increase in fetal deaths n, California, USA morbidity and morbidity above 95 1976 from 1959 to mmHg 1967

multiparo us women from a populatio n with a high rate of congenital CMV infection
us women from a populatio n with a high rate of congenital CMV infection

0.97, 95%CI 0.81 to 1.16, p=0.73 Lower rates of depression and highest scores,
Rate of progression greater in women enrolled at less than 30 weeks compared with 34 to 35 weeks, p = 0.008